Literature DB >> 1518862

Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo.

S Raychaudhuri1, M Tonks, F Carbone, T Ryskamp, W J Morrow, N Hanna.   

Abstract

Cytotoxic T lymphocytes (CTL) are induced specifically against viral and tumor antigens presented by major histocompatibility complex class I molecules on the surface of infected or transformed cells. Intracellular synthesized antigens are processed and associated with class I antigens within cells before presentation on the cell surface. Because of this special requirement for CTL induction, exogenous soluble antigens do not, in general, induce specific CTL responses. To overcome this problem, various laboratories have resorted to the use of vaccinia virus and other replicating expression vectors for intracellular antigen delivery leading to the stimulation of humoral and cell-mediated immunity to specific proteins. However, for human use it is safer to use purified and defined antigens for inducing immune responses. Using soluble ovalbumin and human immunodeficiency virus glycoprotein gp120, we have explored the possibility of using an antigen formulation consisting of squalane and Tween 80 to elicit antigen-specific CTL responses in mice. We have demonstrated that this antigen formulation is a potent inducer of CD8+, class I-restricted, antigen-specific CTLs. The CTL priming induced by soluble antigen in squalane/Tween 80 resembles the reported response to the vaccinia recombinant containing human immunodeficiency virus envelope protein and by splenocytes cytoplasmically loaded with soluble ovalbumin. The ramifications of these findings for vaccine development are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1518862      PMCID: PMC49907          DOI: 10.1073/pnas.89.17.8308

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Association of class I major histocompatibility heavy and light chains induced by viral peptides.

Authors:  A Townsend; C Ohlén; J Bastin; H G Ljunggren; L Foster; K Kärre
Journal:  Nature       Date:  1989-08-10       Impact factor: 49.962

2.  HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells.

Authors:  R P Johnson; A Trocha; L Yang; G P Mazzara; D L Panicali; T M Buchanan; B D Walker
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

3.  Antigen recognition. Class discrimination in the world of immunology.

Authors:  M J Bevan
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

4.  Enhancement of tumor growth correlates with suppression of the tumor-specific cytolytic T lymphocyte response in mice chronically infected by Trypanosoma cruzi.

Authors:  F Plata
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

Review 5.  Vaccinia virus: a tool for research and vaccine development.

Authors:  B Moss
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

6.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.

Authors:  H Takahashi; T Takeshita; B Morein; S Putney; R N Germain; J A Berzofsky
Journal:  Nature       Date:  1990-04-26       Impact factor: 49.962

7.  Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells.

Authors:  S A Hammond; E Obah; P Stanhope; C R Monell; M Strand; F M Robbins; W B Bias; R W Karr; S Koenig; R F Siliciano
Journal:  J Immunol       Date:  1991-03-01       Impact factor: 5.422

8.  Cytotoxic T-cell immunity to influenza.

Authors:  A J McMichael; F M Gotch; G R Noble; P A Beare
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

9.  New use of BCG for recombinant vaccines.

Authors:  C K Stover; V F de la Cruz; T R Fuerst; J E Burlein; L A Benson; L T Bennett; G P Bansal; J F Young; M H Lee; G F Hatfull
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

10.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

Authors:  B D Walker; C Flexner; K Birch-Limberger; L Fisher; T J Paradis; A Aldovini; R Young; B Moss; R T Schooley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  9 in total

1.  Cross-linked protein crystals for vaccine delivery.

Authors:  N St Clair; B Shenoy; L D Jacob; A L Margolin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

Authors:  G T Layton; S J Harris; J Myhan; D West; F Gotch; M Hill-Perkins; J S Cole; N Meyers; S Woodrow; T J French; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide.

Authors:  B Nardelli; J P Tam
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

4.  Tat-mediated protein delivery can facilitate MHC class I presentation of antigens.

Authors:  P Moy; Y Daikh; B Pepinsky; D Thomas; S Fawell; J Barsoum
Journal:  Mol Biotechnol       Date:  1996-10       Impact factor: 2.695

5.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

6.  Induction of cell death by saponin and antigen delivery.

Authors:  Ching-An Wu; Ya-Wun Yang
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

7.  Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant.

Authors:  J B De Souza; I T Ling; S A Ogun; A A Holder; J H Playfair
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

8.  A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1.

Authors:  R W Wilkinson; E L Ross; A E Lee-MacAry; R Laylor; J Burchell; J Taylor-Papadimitriou; D Snary
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

9.  Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.

Authors:  D J Peace; J W Smith; W Chen; S G You; W L Cosand; J Blake; M A Cheever
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.